Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B
© 2023 Japan Society of Hepatology..
AIM: Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are considered safe nucleoside/nucleotide analogs (NA) for the kidney. This study aimed to investigate the long-term effects of ETV or TAF on renal function in elderly patients with chronic hepatitis B (CHB) in Japan.
METHODS: The study included 246 CHB patients treated with ETV (184 patients) or TAF (62 patients) for at least 2 years. These patients were divided into two groups: those <65 years of age (130 patients) and those ≥65 years of age (116 patients). The effects of the NAs on renal functions were examined by comparing the estimated glomerular filtration rates (eGFR) from baseline to 2 years between the two groups.
RESULTS: The change in eGFR from baseline to 1 or 2 years after treatment was significantly decreased in both groups. However, the amount of change at 1 and 2 years was significantly greater in the group aged ≥65 years than in the group aged <65 years. The amount of change in eGFR from baseline to 1 and 2 years after treatment was significantly greater in the group aged ≥65 years than in the group aged <65 years, regardless of the type of NA, the prior treatment history, cirrhosis/chronic hepatitis, hypertension, dyslipidemia, and diabetes. Additionally, logistic regression analysis showed that age ≥65 years was independently associated with a decreased eGFR after 2 years of NA treatment.
CONCLUSIONS: Long-term administration of NA to CHB patients over 65 years of age should be carefully monitored for renal impairment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Hepatology research : the official journal of the Japan Society of Hepatology - 54(2024), 3 vom: 25. März, Seite 252-260 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tanaka, Misako [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic hepatitis B |
|---|
| Anmerkungen: |
Date Revised 02.03.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1111/hepr.13982 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363897216 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363897216 | ||
| 003 | DE-627 | ||
| 005 | 20240303231842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hepr.13982 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1315.xml |
| 035 | |a (DE-627)NLM363897216 | ||
| 035 | |a (NLM)37897705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tanaka, Misako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Japan Society of Hepatology. | ||
| 520 | |a AIM: Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are considered safe nucleoside/nucleotide analogs (NA) for the kidney. This study aimed to investigate the long-term effects of ETV or TAF on renal function in elderly patients with chronic hepatitis B (CHB) in Japan | ||
| 520 | |a METHODS: The study included 246 CHB patients treated with ETV (184 patients) or TAF (62 patients) for at least 2 years. These patients were divided into two groups: those <65 years of age (130 patients) and those ≥65 years of age (116 patients). The effects of the NAs on renal functions were examined by comparing the estimated glomerular filtration rates (eGFR) from baseline to 2 years between the two groups | ||
| 520 | |a RESULTS: The change in eGFR from baseline to 1 or 2 years after treatment was significantly decreased in both groups. However, the amount of change at 1 and 2 years was significantly greater in the group aged ≥65 years than in the group aged <65 years. The amount of change in eGFR from baseline to 1 and 2 years after treatment was significantly greater in the group aged ≥65 years than in the group aged <65 years, regardless of the type of NA, the prior treatment history, cirrhosis/chronic hepatitis, hypertension, dyslipidemia, and diabetes. Additionally, logistic regression analysis showed that age ≥65 years was independently associated with a decreased eGFR after 2 years of NA treatment | ||
| 520 | |a CONCLUSIONS: Long-term administration of NA to CHB patients over 65 years of age should be carefully monitored for renal impairment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic hepatitis B | |
| 650 | 4 | |a elderly patient | |
| 650 | 4 | |a glomerular filtration rate | |
| 650 | 4 | |a nucleos(t)ide analog | |
| 650 | 4 | |a renal function | |
| 700 | 1 | |a Akahane, Takemi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawaratani, Hideto |e verfasserin |4 aut | |
| 700 | 1 | |a Yorioka, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Aritoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Asada, Shohei |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuda, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Iwai, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujinaga, Yukihisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Norihisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Koh |e verfasserin |4 aut | |
| 700 | 1 | |a Kaji, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Namisaki, Tadashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshiji, Hitoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology research : the official journal of the Japan Society of Hepatology |d 1998 |g 54(2024), 3 vom: 25. März, Seite 252-260 |w (DE-627)NLM096511133 |x 1386-6346 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:3 |g day:25 |g month:03 |g pages:252-260 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hepr.13982 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 3 |b 25 |c 03 |h 252-260 | ||